Dermatology

Cutera to Announce Fourth Quarter and Full-Year 2023 Results on March 21, 2024

Retrieved on: 
Friday, March 1, 2024

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024.

Key Points: 
  • Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024.
  • The Company intends to file its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 and restated Quarterly Reports for the first and second quarters of 2023 in the week beginning March 4, 2024.
  • As previously reported, the delay in filing the Quarterly Reports was due to the identification of an inventory shortfall relative to the system of record.
  • The Company’s management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m.

Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA

Retrieved on: 
Thursday, February 29, 2024

LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.

Key Points: 
  • LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
  • LEO Pharma delivered 11.4 billion in revenue, corresponding to 7% revenue growth in 2023.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.

DermTech Reports Fourth-Quarter 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results.
  • “We’ve aligned our commercial effort with the aim to maximize revenue by focusing on existing customers and reimbursed tests.
  • Total revenue was $3.9 million, a 31 percent increase from the fourth quarter of 2022, driven by higher test revenue.
  • Cash, cash equivalents, restricted cash and short-term marketable securities were $59.3 million as of December 31, 2023.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

An Invitation to Innovaderm’s 5th Breakfast Event, This Year’s Focus is on Alopecia Areata (AA)

Retrieved on: 
Thursday, February 22, 2024

This year, the event will focus on the world of Alopecia Areata (AA).

Key Points: 
  • This year, the event will focus on the world of Alopecia Areata (AA).
  • They will be sharing thoughts on “Clinical Evaluations and Current Treatments for AA” and “Experimental and Future Treatments of AA” respectively.
  • The Breakfast Event will serve as a platform to engage in insightful discussions and network with industry professionals, clinicians, and peers in dermatology clinical research.
  • If you plan to attend AAD in San Diego, we highly recommend reserving your place at our Breakfast Event without further ado.

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, February 21, 2024

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against InMode Ltd. (“InMode” or “the Company”) (NASDAQ: INMD) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against InMode Ltd. (“InMode” or “the Company”) (NASDAQ: INMD) and certain of its officers.
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

Retrieved on: 
Monday, February 19, 2024

Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.

Key Points: 
  • Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
  • Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
  • Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
  • NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications.

Global Times: How two sessions serve as bridge between people and government, help authorities formulate policies

Retrieved on: 
Friday, March 8, 2024

Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.

Key Points: 
  • Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.
  • In 2021, China also for the first time included a rare disease treatment in its National Reimbursement Drug List.
  • These moves together benefited thousands of Chinese suffering from rare diseases, including spinal muscular atrophy (SMA) patient Zhang Jianuo and his parents.
  • Motions and proposals during the two sessions are crucial pathways for addressing issues impacting people's livelihood, and they're becoming increasingly effective.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.

Key Points: 
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • Brandt noted, "Mohs micrographic surgery has been the gold standard of care for the treatment of nonmelanoma skin cancer (NMSC) for more than 50 years.
  • "SkinCure Oncology," Brandt continued, "is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • The new devices will feature technology for which SkinCure Oncology was recently awarded U.S. patent coverage.

Golden State Dermatology Announces New Partnership in Folsom, CA

Retrieved on: 
Wednesday, March 6, 2024

FOLSOM, Calif., March 6, 2024 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Dr. David No's practice, the Dermatology Center of Northern California (DCNC).

Key Points: 
  • FOLSOM, Calif., March 6, 2024 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Dr. David No's practice, the Dermatology Center of Northern California (DCNC).
  • DCNC offers a full spectrum of medical dermatology and offers popular cosmetic treatments such as cosmetic injectables, laser treatments, and body contouring.
  • To learn more about Golden State Dermatology, visit GoldenStateDermatology.com .
  • The founder of Golden State Dermatology, Edward Becker, MD said, "We stand with our clinicians, empowering them in our established and emerging markets to deliver exceptional patient-centered care.